Flores et al. demonstrated that HSC CCR2+ migrate from bone-marrow to intracranial PD-L1 resistant brain tumours (GBM and medulloblastoma), giving rise to APCs like Mo-DCs, which stimulate the CD8+ T-response against tumour cells. The gene discussed is CD8A; the disease is neoplasm.